NAOV
NanoVibronix, Inc.
Set alert
- YTD
- -70.72%
- 1 year
- -71.21%
- Open
- 1.84
- Prev close
- 1.90
- Mkt cap
- 2.03M
- Vol
- 98.18K
- Avg vol
- 394.93K
- EPS
- -1.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.78
- High
- 1.92
- Forward P/E
- -0.67
- Beta
- 1.51
- Short ratio
- 0.47
- Inst. own
- 13.49%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.6259
- 200-d avg
- 0.702115
- 1y target
- 0.00
Key statistics
- Market cap
- 2.03M
- Enterprise value
- -257.80K
- Trailing P/E
- 0.00
- Forward P/E
- -0.67
- PEG ratio
- 0.00
- Price / sales
- 0.60
- Price / book
- 0.28
- EPS (TTM)
- -1.23
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -83.49%
- Revenue (TTM)
- 3.37M
- Revenue growth
- 177.90%
- Free cash flow
- -861.75K
- Total cash
- 2.17M
- Total debt
- 133.00K
- Return on equity
- -140.59%
- Shares outstanding
- 3.75M
- Short % of float
- 4.71%
- 50-day average
- 0.6259
- 200-day average
- 0.702115
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.36 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.25 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.23 | — | — |
| Apr 8, 2024 | Dec 1, 2023 | 0.00 | -0.39 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.42 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.65 | — | — |
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- nanovibronix.com
News
- ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders
- ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities
- ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
- ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
- ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research
- ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
- NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED'
- Head to Head Review: Veracyte (NASDAQ:VCYT) vs. Nanovibronix (NASDAQ:NAOV)
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on NAOV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MIKA THOMAS R | Director | Purchase | Jan 4, 2023 | 50,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.43% | 278,708 | 150.86K | Sep 29, 2024 |
| Vanguard Group Inc | 0.80% | 30,194 | 16.34K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.71% | 26,600 | 14.40K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.63% | 23,791 | 12.88K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.61% | 22,844 | 12.37K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.56% | 21,195 | 11.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.80% | 30,194 | 16.34K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 17,248 | 9.34K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 1,952 | 1.06K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 1,540 | 833 | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,284 | 695 | Oct 30, 2024 |